Articles de revue sur le cancer du poumon - Dernières parutions

InTextoResearch, agence d'information scientifique


InTextoResearch vous informe sur les dernières parutions d'articles de
revue sur le cancer du poumon (5 novembre 2007):

Oncogene and tumor-suppressor gene products as serum biomarkers in
occupational-derived lung cancer.
Helmig S, Schneider J.
Expert Rev Mol Diagn. 2007 Sep;7(5):555-68.

Lung cancer in never smokers--a different disease.
Sun S, Schiller JH, Gazdar AF.
Nat Rev Cancer. 2007 Oct;7(10):778-90.

Computer-aided detection of pulmonary nodules in computed tomography:
analysis and review of the literature.
Saba L, Caddeo G, Mallarini G.
J Comput Assist Tomogr. 2007 Jul-Aug;31(4):611-9.

Emerging drugs for non-small-cell lung cancer.
Felip E, Santarpia M, Rosell R.
Expert Opin Emerg Drugs. 2007 Sep;12(3):449-60.

Definitive chemoradiation for the treatment of locally advanced non
small-cell lung cancer.
Blackstock AW, Govindan R.
J Clin Oncol. 2007 Sep 10;25(26):4146-52.

Limited-stage small-cell lung cancer: the current status of combined-
modality therapy.
Socinski MA, Bogart JA.
J Clin Oncol. 2007 Sep 10;25(26):4137-45.

Targeted therapies in lung cancer: a tribute to advancements in
clinical research.
McGee L.
ONS Connect. 2007;22(8 Suppl):27-8. Review.

Third-generation chemotherapy agents in the treatment of advanced non-
small cell lung cancer: a meta-analysis.
Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski
MA.
J Thorac Oncol. 2007 Sep;2(9):845-53.

Current status of second-line treatment and novel therapies for small
cell lung cancer.
Tiseo M, Ardizzoni A.
J Thorac Oncol. 2007 Aug;2(8):764-72.

Mucinous bronchioloalveolar carcinoma of lung with a rhabdoid
component--report of a case and review of the literature.
Song DE, Jang SJ, Black J, Ro JY.
Histopathology. 2007 Sep;51(3):427-30.

Motexafin gadolinium injection for the treatment of brain metastases
in patients with non-small cell lung cancer.
Thomas SR, Khuntia D.
Int J Nanomedicine. 2007;2(1):79-87.

CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer
therapy.
Murad YM, Clay TM, Lyerly HK, Morse MA.
Expert Opin Biol Ther. 2007 Aug;7(8):1257-66.

Dedifferentiated chondrosarcoma of the lung: case report and review of
the literature.
Steurer S, Huber M, Lintner F.
Clin Lung Cancer. 2007 Jul;8(7):439-42.

Erlotinib as a single agent in select subsets of patients with
advanced non-small-cell lung cancer.
Carrion RP, Gracian AC, Hernandez PS.
Clin Lung Cancer. 2007 Jul;8(7):425-8.

Dual inhibition: combining epidermal growth factor-targeted therapies
in non-small-cell lung cancer.
Ho C, Davies A, Mack P, Gandara D.
Clin Lung Cancer. 2007 Jul;8(7):420-4.

The potential of death receptor 4- and 5-directed therapies in the
treatment of lung cancer.
Camidge DR.
Clin Lung Cancer. 2007 Jul;8(7):413-9.

L-BLP25: a peptide vaccine strategy in non small cell lung cancer.
Sangha R, Butts C.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4652-4.

Incorporating bortezomib into the treatment of lung cancer.
Davies AM, Lara PN Jr, Mack PC, Gandara DR.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4647-51.

Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its
potential application as an anticancer agent in lung cancer.
Herbst RS, Oh Y, Wagle A, Lahn M.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4641-6.

The role of phosphoinositide 3-kinase pathway inhibitors in the
treatment of lung cancer.
Engelman JA.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4637-40.

Antagonism of platelet-derived growth factor receptor in non small
cell lung cancer: rationale and investigations.
Bauman JE, Eaton KD, Martins RG.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4632-6.

Rationale for a phase I trial of erlotinib and the mammalian target of
rapamycin inhibitor everolimus (RAD001) for patients with relapsed non
small cell lung cancer.
Johnson BE, Jackman D, Janne PA.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4628-31.

Vascular endothelial growth factor trap in non small cell lung cancer.
Riely GJ, Miller VA.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4623-7.

Vascular endothelial growth factor receptor tyrosine kinase inhibitors
vandetanib (ZD6474) and AZD2171 in lung cancer.
Hanrahan EO, Heymach JV.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4617-22.

Bevacizumab in non small cell lung cancer.
Sandler A.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4613-6.

Selecting patients for treatment with epidermal growth factor tyrosine
kinase inhibitors.
Bonomi PD, Buckingham L, Coon J.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4606-12.

Is there a role for cetuximab in non small cell lung cancer?
Morgensztern D, Govindan R.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4602-5.

Antibodies to the epidermal growth factor receptor in non small cell
lung cancer: current status of matuzumab and panitumumab.
Socinski MA.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4597-601.

HKI-272 in non small cell lung cancer.
Wong KK.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4593-6.

Erlotinib: recent clinical results and ongoing studies in non small
cell lung cancer.
Perez-Soler R.
Clin Cancer Res. 2007 Aug 1;13(15 Pt 2):s4589-92.

Targeted therapies in small-cell lung cancer.
Fernainy K, Saba N.
Expert Opin Ther Targets. 2007 Aug;11(8):1033-41.

Bevacizumab and non-small-cell lung cancer: starving the enemy to
survive.
Grossi F, Aita M.
Expert Opin Biol Ther. 2007 Jul;7(7):1107-19.

Smoking and lung cancer: future research directions.
Haussmann HJ.
Int J Toxicol. 2007 Jul-Aug;26(4):353-64.

Pulmonary large cell neuroendocrine carcinoma: its place in the
spectrum of pulmonary carcinoma.
Iyoda A, Hiroshima K, Nakatani Y, Fujisawa T.
Ann Thorac Surg. 2007 Aug;84(2):702-7.

(contact pour InTextoResearch: Marc Lacroix, Baelen, Wallonie,
Belgique - scimedweb@mail.com)